The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Secondary Lymphoid-Tissue Chemokine, SLC, a CC Chemokine with a Significant Antitumor Activity in Murine Lymphoma.
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Honoraria - Caris Life Sciences; Celgene; Sirtex Medical
Consulting or Advisory Role - Caris Life Sciences; Celgene; Perthera; Sirtex Medical
Research Funding - Celldex (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Perthera; Sirtex Medical
 
Christian Diego Rolfo
Consulting or Advisory Role - Mylan
Speakers' Bureau - Boehringer Ingelheim; MSD; Novartis
Research Funding - Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Ignyta; Lilly; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; Lycera; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Pratik S. Multani
Employment - Ignyta
Leadership - Ignyta
Stock and Other Ownership Interests - Ignyta
 
Edna Chow Maneval
Employment - Ignyta
 
Ignacio Garrido-Laguna
No Relationships to Disclose